FLX Bio, Inc. logo

FLX Bio, Inc.

FLX Bio, Inc. is a startup, clinical stage biotechnology company developing immunotherapeutics for the treatment of immunoonclology disorders..

FLX Bio, is a spinoff from Flexus Biosciences and was established to continue to advance immuno-oncology pipeline of Agents for Reversal of Tumor Immunosuppression (ARTIS), which were not acquired by Bristol-Myers Squibb in Flexus Bioscience acquisition in Feb 2015.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttp://www.flxbio.com
Founded2015
Disease Focus
Development Stage
STOCK CODENon Listed
Address
561 Eccles Avenue, CA,94080
South San Francisco
United States
Email
Contact Number
+1 650 489 9000

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/flx-bio” connections=”true” suffix=””]

In Nov 2016, Cofactor Genomics partnered with FLX Bio, to develop a novel RNA-based IO analysis platform using Cofactors RNA signature technology, Sigmund, to analyze the immune response of cancer patients.

In April 2016, FLX Bio, raised $50 Mn in Series B financing. The funding includes the participation of Column Group (TCG), Topspin Partners, Kleiner Perkins Caufield & Byers (KPCB) and Celgene. Including both Series A and Series B financing, the company has raised a total of $79 Mn USD.